- Home
- BOWL vs SNDX Comparison
BOWL vs SNDX Comparison
Compare BOWL & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOWL
- SNDX
- Stock Information
- Founded
- BOWL 1900
- SNDX 2005
- Country
- BOWL United States
- SNDX United States
- Employees
- BOWL 11374
- SNDX N/A
- Industry
- BOWL Services-Misc. Amusement & Recreation
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BOWL Consumer Discretionary
- SNDX Health Care
- Exchange
- BOWL Nasdaq
- SNDX Nasdaq
- Market Cap
- BOWL 1.7B
- SNDX 1.4B
- IPO Year
- BOWL N/A
- SNDX 2016
- Fundamental
- Price
- BOWL $10.52
- SNDX $13.63
- Analyst Decision
- BOWL Strong Buy
- SNDX Strong Buy
- Analyst Count
- BOWL 10
- SNDX 11
- Target Price
- BOWL $15.89
- SNDX $37.64
- AVG Volume (30 Days)
- BOWL 637.1K
- SNDX 1.9M
- Earning Date
- BOWL 02-03-2025
- SNDX 11-05-2024
- Dividend Yield
- BOWL 1.85%
- SNDX N/A
- EPS Growth
- BOWL N/A
- SNDX N/A
- EPS
- BOWL N/A
- SNDX N/A
- Revenue
- BOWL $1,187,404,000.00
- SNDX $16,000,000.00
- Revenue This Year
- BOWL $10.34
- SNDX N/A
- Revenue Next Year
- BOWL $6.91
- SNDX N/A
- P/E Ratio
- BOWL N/A
- SNDX N/A
- Revenue Growth
- BOWL 12.45
- SNDX N/A
- 52 Week Low
- BOWL $9.71
- SNDX $13.26
- 52 Week High
- BOWL $15.47
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- BOWL 36.39
- SNDX 29.66
- Support Level
- BOWL $11.39
- SNDX $13.26
- Resistance Level
- BOWL $12.47
- SNDX $14.18
- Average True Range (ATR)
- BOWL 0.53
- SNDX 0.82
- MACD
- BOWL -0.15
- SNDX -0.21
- Stochastic Oscillator
- BOWL 0.89
- SNDX 9.20
About BOWL Bowlero Corp.
Bowlero Corp is a operator of bowling entertainment centers. It operate traditional bowling centers and more upscale entertainment concepts with lounge seating, arcades, enhanced food and beverage offerings, and more robust customer service for individuals and group events, as well as hosting and overseeing professional and non-professional bowling tournaments and related broadcasting.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.